888-969-2592
Kalkine 0
countryflagCA

Abbott Laboratories

Healthcare US ABT

135.4143USD
-0.5957(0.44%)

Last update at 2025-07-01T16:58:00Z

Day Range

134.81137.08
LowHigh

52 Week Range

89.67115.19
LowHigh

Fundamentals

  • Previous Close 136.01
  • Market Cap189629.84M
  • Volume1716600
  • P/E Ratio37.15
  • Dividend Yield2.01%
  • EBITDA9871.00M
  • Revenue TTM39959.00M
  • Revenue Per Share TTM22.95
  • Gross Profit TTM 24579.00M
  • Diluted EPS TTM2.94

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 8306.00M 8211.00M 4968.00M 4077.00M 2873.00M
Minority interest - - 219.00M 213.00M 198.00M
Net income 6933.00M 7071.00M 4495.00M 3687.00M 2368.00M
Selling general administrative 11012.00M 11324.00M 9696.00M 9765.00M 9744.00M
Selling and marketing expenses - - - - -
Gross profit 24511.00M 24538.00M 19605.00M 18673.00M 17872.00M
Reconciled depreciation 2013.00M 2047.00M 3327.00M 3014.00M 3278.00M
Ebit 8362.00M 8425.00M 5357.00M 4532.00M 3789.00M
Ebitda 10696.00M 10749.00M 7592.00M 6659.00M 5967.00M
Depreciation and amortization 2334.00M 2324.00M 2235.00M 2127.00M 2178.00M
Non operating income net other 502.00M 319.00M 157.00M 215.00M 49.00M
Operating income 8362.00M 8425.00M 5357.00M 4532.00M 3650.00M
Other operating expenses 35291.00M 34650.00M 29251.00M 27372.00M 26928.00M
Interest expense 375.00M 490.00M 500.00M 576.00M 721.00M
Tax provision 1373.00M 1140.00M 497.00M 390.00M 539.00M
Interest income 377.00M 491.00M 492.00M 94.00M 105.00M
Net interest income -375.00000M -490.00000M -500.00000M -576.00000M -721.00000M
Extraordinary items - 0.00000M 24.00M 86.00M -96.00000M
Non recurring - - - - -
Other items - - - - -
Income tax expense 1373.00M 1140.00M 497.00M 390.00M 539.00M
Total revenue 43653.00M 43075.00M 34608.00M 31904.00M 30578.00M
Total operating expenses 16149.00M 16113.00M 14248.00M 14141.00M 14222.00M
Cost of revenue 19142.00M 18537.00M 15003.00M 13231.00M 12706.00M
Total other income expense net -56.00000M -214.00000M -389.00000M -455.00000M -56.00000M
Discontinued operations - - 24.00M 24.00M 34.00M
Net income from continuing ops 6933.00M 7071.00M 4471.00M 3687.00M 2334.00M
Net income applicable to common shares 6933.00M 7071.00M 4495.00M 3687.00M 2353.00M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 74438.00M 75196.00M 72548.00M 67887.00M 67173.00M
Intangible assets 10454.00M 12739.00M 14784.00M 17025.00M 18942.00M
Earning assets - - - - -
Other current assets 2663.00M 2346.00M 1867.00M 1786.00M 1568.00M
Total liab 37533.00M 39172.00M 39545.00M 36586.00M 36451.00M
Total stockholder equity 36686.00M 35802.00M 32784.00M 31088.00M 30524.00M
Deferred long term liab - - - - -
Other current liab 8631.00M 7943.00M 7741.00M 6133.00M 5525.00M
Common stock 24709.00M 24470.00M 24145.00M 23853.00M 23512.00M
Capital stock 24709.00M 24470.00M 24145.00M 23853.00M 23512.00M
Retained earnings 35257.00M 31528.00M 27627.00M 25847.00M 24560.00M
Other liab 6579.00M 7815.00M 8209.00M 8307.00M 8080.00M
Good will 22799.00M 23231.00M 23744.00M 23195.00M 23254.00M
Other assets 4917.00M 4059.00M 2784.00M 2443.00M 2192.00M
Cash 9882.00M 9799.00M 6838.00M 3860.00M 3844.00M
Cash and equivalents 9882.00M 9799.00M 6838.00M 3860.00M 3844.00M
Total current liabilities 15489.00M 13105.00M 11907.00M 10863.00M 9012.00M
Current deferred revenue - - - - 305.00M
Net debt 7834.00M 9207.00M 12811.00M 15034.00M 15722.00M
Short term debt 2251.00M 754.00M 220.00M 1478.00M 207.00M
Short long term debt 2251.00M 754.00M 220.00M 1478.00M 207.00M
Short long term debt total 17716.00M 19006.00M 19649.00M 18894.00M 19566.00M
Other stockholder equity -15229.00000M -11822.00000M -10042.00000M -10147.00000M -9962.00000M
Property plant equipment 9162.00M 8959.00M 9029.00M 8038.00M 7563.00M
Total current assets 25224.00M 24239.00M 20441.00M 15667.00M 14632.00M
Long term investments 766.00M 816.00M 821.00M 883.00M 897.00M
Net tangible assets 10955.00M -2189.00000M 3367.00M -70.00000M -11672.00000M
Short term investments 288.00M 450.00M 310.00M 280.00M 242.00M
Net receivables 8881.00M 6487.00M 6414.00M 5425.00M 5182.00M
Long term debt 14522.00M 17296.00M 18527.00M 16661.00M 19359.00M
Inventory 6173.00M 5157.00M 5012.00M 4316.00M 3796.00M
Accounts payable 4607.00M 4408.00M 3946.00M 3252.00M 2975.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity 219.00M 222.00M 219.00M 213.00M 198.00M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -8051.00000M -8374.00000M -8946.00000M -8465.00000M -7586.00000M
Additional paid in capital - - - - -
Common stock total equity 24709.00M 24470.00M 24145.00M 23853.00M 23512.00M
Preferred stock total equity - - - - -
Retained earnings total equity 35257.00M 31528.00M 27627.00M 25847.00M 24560.00M
Treasury stock - -11822.00000M -10042.00000M -10147.00000M -9962.00000M
Accumulated amortization - - - - -
Non currrent assets other - - - 52220.00M 17.00M
Deferred long term asset charges - - - - -
Non current assets total 49214.00M 50957.00M 52107.00M 52220.00M 52541.00M
Capital lease obligations 943.00M 956.00M 902.00M 755.00M -
Long term debt total 14522.00M 17296.00M 18527.00M 16661.00M 19359.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -33.00000M -96.00000M -73.00000M -82.00000M -58.00000M
Change to liabilities 37.00M 380.00M 1152.00M -325.00000M 533.00M
Total cashflows from investing activities -1740.00000M -2008.00000M -2215.00000M -1815.00000M -1356.00000M
Net borrowings 47.00M -248.00000M -50.00000M -1599.00000M -8450.00000M
Total cash from financing activities -7636.00000M -5494.00000M -2779.00000M -4289.00000M -10391.00000M
Change to operating activities -75.00000M -312.00000M -627.00000M -138.00000M 23.00M
Net income 6933.00M 7071.00M 4495.00M 3687.00M 2368.00M
Change in cash 83.00M 2961.00M 2978.00M 16.00M -5563.00000M
Begin period cash flow 9799.00M 6838.00M 3860.00M 3844.00M 9407.00M
End period cash flow 9882.00M 9799.00M 6838.00M 3860.00M 3844.00M
Total cash from operating activities 9581.00M 10533.00M 7901.00M 6136.00M 6300.00M
Issuance of capital stock - - - - -
Depreciation 3267.00M 3538.00M 3327.00M 3014.00M 3278.00M
Other cashflows from investing activities 70.00M -27.00000M 35.00M -95.00000M 96.00M
Dividends paid -3309.00000M -3202.00000M -2560.00000M -2270.00000M 1974.00M
Change to inventory -1413.00000M -456.00000M -493.00000M -593.00000M -514.00000M
Change to account receivables -68.00000M -383.00000M -924.00000M -275.00000M -190.00000M
Sale purchase of stock -3795.00000M -2299.00000M -403.00000M -718.00000M -238.00000M
Other cashflows from financing activities 221.00M 55.00M -11.00000M 2140.00M 4254.00M
Change to netincome 685.00M 640.00M 546.00M 582.00M 644.00M
Capital expenditures 1777.00M 1885.00M 2177.00M 1638.00M 1394.00M
Change receivables -68.00000M -383.00000M -924.00000M -275.00000M -190.00000M
Cash flows other operating 140.00M -257.00000M -202.00000M 46.00M 181.00M
Exchange rate changes - - - - -
Cash and cash equivalents changes 205.00M 3031.00M 2907.00M 32.00M -5447.00000M
Change in working capital -1519.00000M -771.00000M -892.00000M -1331.00000M -148.00000M
Stock based compensation 685.00M 640.00M 546.00M 519.00M 477.00M
Other non cash items 215.00M 55.00M 425.00M 247.00M 32.00M
Free cash flow 7804.00M 8648.00M 5724.00M 4498.00M 4906.00M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ABT
Abbott Laboratories		 -0.5957 0.44% 135.41 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation		 0.20 0.05% 395.83 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 0.77 0.88% 87.94 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -2.4 2.23% 105.01 68.17 24.57 5.85 4.26 6.46 26.80
SEMHF
Siemens Healthineers AG		 0.10 0.18% 55.00 39.57 21.32 3.01 3.29 2.95 16.92

Reports Covered

Stock Research & News

View All

Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Abbott Laboratories

100 Abbott Park Road, North Chicago, IL, United States, 60064-6400

Key Executives

Name Title Year Born
Mr. Robert B. Ford Chairman, Pres & CEO 1974
Mr. Robert E. Funck Jr. Exec. VP of Fin. & CFO 1961
Mr. Hubert L. Allen Exec. VP, Gen. Counsel & Sec. 1966
Mr. Daniel Gesua Sive Salvadori Exec. VP and Group Pres of Established Pharmaceuticals & Nutritional Products 1979
Ms. Andrea F. Wainer Exec. VP of Rapid & Molecular Diagnostics 1970
Mr. Scott Michael Leinenweber VP of Investor Relations, Licensing & Acquisitions 1972
James E. Young VP and Chief Ethics & Compliance Officer NA
Ms. Melissa Brotz VP of Public Affairs & Corp. Marketing NA
Ms. Elaine R. Leavenworth Sr. VP and Chief Marketing & External Affairs Officer 1959
Ms. Mary K. Moreland Exec. VP of HR 1966

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.